September 23, 2021 7:36am

Yesterday, the sector closed with a weak aftermarket after what I call a skimpy session while Q3 slowly ebbs next week

Pre-open indications: 4 BUYs and 2 SELLs

Earnings: Applied Genetic Technologies (AGTC) – reports today, 9/23

What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity!

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.47% (+162 points), S&P futures are UP +0.52% (+23 point) and NASDAQ futures are UP +0.54% (+82 point)

 

U.S. stocks futures were up fueling a positive open on Thursday,

European stocks opened higher,

Asia-Pacific stocks were mostly higher.

 

Data Docket: The Department of Labor will release initial jobless claims number

 

Henry’omics:

Yesterday, set the tone but, not the flavor of the week and months soon to be end as indexes finished higher after the Fed kept benchmark interest rates unchanged, while indicating no immediate intention of removing stimulus policies.

The Dow gained roughly 340 points, or 1%, for its first positive session in five and best day since July 20. The S&P advanced 0.95%, also snapping a four-day losing streak and registering its best day since July 23. The Nasdaq finished the session 1.02% higher, while the Russell 2000 outperformed on the session, rising 1.48%.

For the month, the Nasdaq is off by -2%.

 

If you didn’t remember what happen at Wednesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Q3/21:

  • September, 1 holiday, 8 positive and 7 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

Applied Genetic Technologies (AGTC) – reports today, 9/23

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles: WHAT happening in the usual “pump/promote”?

  • Tuesday closed down -$0.45 with 3,833 shares traded after Tuesday’s +$0.25 with 654 shares traded following Monday closing down -$0.26 to $3.40 with 563 shares traded after last Friday’s 129 shares traded dropping the share price -$0.38 after last Thursday closed -$0.04 with 14,641 shares traded

Question: WERE BSTG’s Q2 filing AUDITED by any accounting firm or left UNAUDITED for investors?

 

BUY:

Solid Biosciences (SLDB) closed down -$0.20 to $3.00 after Tuesday’s $ and Monday’s $ with a positive +$0.08 or +2.6% pre-market indication as it “finally” report positive 1.5-year functional data and patient-reported outcome measures (Pediatric Outcomes Data Collection Instrument, or PODCI) for patients 4-6 in the ongoing IGNITE DMD P1/2 clinical trial of SGT-001.

CRISP Therapeutics (CRSP) closed up +$0.56 to $117.81 after Tuesday’s +$0.78 to $117.25, Monday’s down -$8.05 to $116.47 after last Friday’s +$7.10 to $124.52 and has a positive +$1.71 or +1.45% pre-market indication.

Editas Medicine (EDIT) closed up +$0.43 to $59.11 after Tuesday’s $58.68 and Monday’s $58.20 with a positive +$0.39 or +0.66% pre-market indication.

Global Blood Therapeutics (GBT) closed down -$0.86 to $26.14 after Tuesday’s -$0.10 to $27.00 and Monday’s $27.10 with a positive +$1.01 or +3.83% pre-market indication.

 

SELL:

Fate Therapeutics (FATE) closed up +$0.76 to $68.89 after Tuesday’s +$0.65 to $44.23 and Monday’s $43.58 with a negative -$1.98 or -2.87% pre-market indication,

 

The BOTTOM LINE: I have that “twitch” concerning the sector’s movement, it will enjoy the ride with the market’s high; however, the wall of worry associated with anxiety and fear need to be considered.

I’m … still watching my portfolio’s “six” today, it is fraught with upcoming obstacles …

Not yielding, I keep reinforcing the theme that increased stock market volatility suppresses the stem, cell and gene therapy sector.

I maintain, the recent stem, cell and gene therapy sector investors should be a bit more defensive, limiting new buys and perhaps curtailing overexposure to electronic trading risks.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.